EYLEA® meets primary endpoint in two Phase III trials for the treatment of diabetic macular oedema

Bayer HealthCare has announced that EYLEA (aflibercept solution for injection, known in the scientific literature as VEGF Trap-Eye) has achieved the primary endpoint in two pivotal phase III trials for the treatment of diabetic macular oedema (DMO),1 the leading cause of sight loss in people suffering from diabetes…